Le Lézard
Classified in: Health
Subjects: PER, ACC

Orexo´s Nomination Committee for the Annual General Meeting 2025


UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises of the following members:

The Nomination Committee represents approximately 34 percent of the number of votes in the company as of August 31, 2024.

The Nomination Committee will prepare proposals to the AGM regarding Chairman of the meeting, Chairman of the Board, Board members, Board member fees, any remuneration for committee work, and fees to the auditor, as well as principles for the composition of the Nomination Committee.

The Nomination Committee's proposals will be presented in the Notice of the AGM and on Orexo's website, www.orexo.com. Shareholders who want to submit proposals to the Nomination Committee can do this by sending an e-mail to [email protected] (subject "Nomination Committee") at latest March 7, 2025.

Orexo AB (publ.)

Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: [email protected]

About Orexo

Orexo is a Swedish pharmaceutical company with nearly 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

The information was submitted for publication at 8 am CET on October 4, 2024. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-s-nomination-committee-for-the-annual-general-meeting-2025,c4046784

 

SOURCE Orexo


These press releases may also interest you

at 22:09
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral...

at 20:19
Kenvue Canada Inc., a division of Kenvue Inc. ("Kenvue"), the world's largest pure-play consumer health company by revenue and maker of iconic brands such as Tylenol®, Aveeno, Listerine® and Neutrogena®, announced the completion of its newly...

at 19:55
Hugel Inc., a leading global medical aesthetics company, said on Tuesday that WELLAGE, its clinical derma cosmetics brand for skin wellness, joined the festival K-beauty Boost in NYC 2024 at the Korean Cultural Center New...

at 19:09
Acoustiic Inc. has received a research funding agreement from the Focused Ultrasound Foundation (FUS) to adapt their WaveMatrixtm platform to explore the therapeutic applications of ultrasound in companion animals. Acoustiic's platform provides an...

at 18:54
ScriptsMD is an innovative healthcare solution that provides Americans with affordable access to semaglutide weight loss treatment while addressing nationwide medication shortages. The company's comprehensive program delivers semaglutide at just $239...

at 18:35
Algernon Pharmaceuticals Inc.  (the "Company" or "Algernon") a Canadian clinical stage pharmaceutical development company announces that it has extended the expiry date of an aggregate of 4,752,969 outstanding warrants (the "2023 Warrants"). The...



News published on and distributed by: